Stay updated on Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.

Latest updates to the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page now displays a new site revision label, Revision: v3.6.3, replacing the previous Revision: v3.6.0. This indicates a software update to the site rather than changes to the clinical study information shown on the page.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe investigators section was updated to include Hiroaki Akamatsu and adjust institution references. New help/navigation items were added (How to Read a Study Record, Common Questions, How to Join a Study), the Intervention/Treatment label formatting was updated, and the revision tag changed from v3.5.5 to v3.6.0.SummaryDifference2%

- Check30 days agoChange DetectedThe page now shows Revision: v3.5.5, indicating a new site revision. This replaces the previous Revision: v3.5.4 and reflects a minor platform update.SummaryDifference0.1%

- Check51 days agoChange DetectedRevision: v3.5.4 was added to the page, replacing the previous v3.5.3. This indicates a site software/version update for the ClinicalTrials.gov page, with no evident changes to the study's details or eligibility criteria.SummaryDifference0.1%

- Check73 days agoChange DetectedThe study page’s footer revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a site/version update rather than a change to the trial information itself.SummaryDifference0.1%

- Check80 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.